COMPANY

AbVacc

HQ: Rockville, MD source · abvacc.com ↗ · Mid-Atlantic

Keywords: vaccine infectious disease infectious diseases antibody bacterial infectious disease Ebola virus disease

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

22NIH grants

NIH awards 22

Annual award amounts. Total $14.5M.

Sep 17, 2026 NIH award 5R01AI193221-02 FY2026: $642,054 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. A multimodal approach for immunotherapy of Staph source ↗
May 19, 2026 NIH award 5R44AI179371-03 FY2026: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Monoclonal Antibody Cocktail for Treatment of Marbu source ↗
Feb 19, 2026 NIH award 5R01AI111205-10 FY2026: $697,200 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Multivalent Toxoid Vaccine for recurrent Staphyl source ↗
Aug 22, 2025 NIH award 1R01AI193221-01 FY2025: $638,953 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. A multimodal approach for immunotherapy of Staph source ↗
May 30, 2025 NIH award 4R44AI179371-02 FY2025: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Monoclonal Antibody Cocktail for Treatment of Marbu source ↗
Apr 30, 2025 NIH award 5R44AI177045-03 FY2025: $914,818 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Prophylactic Immunotherapy for Marburg Virus Disease source ↗
Feb 13, 2025 NIH award 5R01AI111205-09 FY2025: $646,138 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Multivalent Toxoid Vaccine for recurrent Staphyl source ↗
Jan 17, 2025 NIH award 5R43AI181292-02 FY2025: $297,099 awarded for that fiscal year; activity R43 (SBIR); PI KAILASAN, SHWETA; recipient as written: ABVACC, INC., ROCKVILLE, MD. Development of a Marburgvirus subunit vaccineadjuv source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93021C00021-P00011-9999-1 FY2025: $21,963 awarded for that fiscal year; activity N01 (OTHER_NIH); PI AMAN, JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Development of T source ↗
Apr 19, 2024 NIH award 5R44AI177045-02 FY2024: $918,483 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Prophylactic Immunotherapy for Marburg Virus Disease source ↗
Mar 28, 2024 NIH award 5R01AI146177-05 FY2024: $619,311 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Protective versus deleterious immune responses t source ↗
Mar 28, 2024 NIH award 5R01AI111205-08 FY2024: $649,379 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Multivalent Toxoid Vaccine for recurrent Staphyl source ↗
Feb 26, 2024 NIH award 1R43AI181292-01 FY2024: $299,528 awarded for that fiscal year; activity R43 (SBIR); PI KAILASAN, SHWETA; recipient as written: ABVACC, INC., ROCKVILLE, MD. Development of a Marburgvirus subunit vaccineadjuv source ↗
Aug 11, 2023 NIH award 1R44AI179371-01 FY2023: $293,392 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Monoclonal Antibody Cocktail for Treatment of Marburg source ↗
May 26, 2023 NIH award 6R42AI122666-06 FY2021: $315,000 awarded for that fiscal year; activity R42 (STTR); PI ADHIKARI, RAJAN P; recipient as written: ABVACC, INC., ROCKVILLE, MD. Infection Site Targeted Antitoxin Antibody (ISTAb source ↗
May 12, 2023 NIH award 1R44AI177045-01 FY2023: $986,248 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Prophylactic Immunotherapy for Marburg Virus Disease source ↗
May 10, 2023 NIH award 6R01AI111205-07 FY2023: $670,570 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Multivalent Toxoid Vaccine for recurrent Staphyl source ↗
Apr 26, 2023 NIH award 6R44AI140932-04 FY2022: $380,000 awarded for that fiscal year; activity R44 (SBIR); PI HOLTSBERG, FREDERICK WAYNE; recipient as written: ABVACC, INC., ROCKVILLE, MD. Development of a Universal Immunotherape source ↗
Apr 25, 2023 NIH award 6R01AI146177-04 FY2023: $663,570 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Protective versus deleterious immune responses t source ↗
Apr 21, 2023 NIH award 6R44AI155309-03 FY2023: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Immunotherapy of MRSA Osteomyelitis source ↗
Apr 20, 2023 NIH award 6R01AI132204-06 FY2021: $166,279 awarded for that fiscal year; activity R01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Rationally Designed Pan-Ebolavirus Vaccine source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93021C00021-P00003-9999-1 FY2023: $1,696,004 awarded for that fiscal year; activity N01 (OTHER_NIH); PI AMAN, M JAVAD; recipient as written: ABVACC, INC., ROCKVILLE, MD. Development source ↗

Funding and NIH signals

NIH award NIH awarded $642K (NIH grant 5R01AI193221-02, continuation, notice Sep 17, 2026); 3 NIH awards totaling $2.34M in the last 12 months. NIH RePORTER 5R01AI193221-02 (Sep 17, 2026)
Evidence (3 events)
- Sep 17, 2026 · NIH RePORTER 5R01AI193221-02
  Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R01AI193221-02; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 642054; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia; Organization type: Domestic For-Profits
- May 19, 2026 · NIH RePORTER 5R44AI179371-03
  Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R44AI179371-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease; Organization type: Domestic For-Profits
- Feb 19, 2026 · NIH RePORTER 5R01AI111205-10
  Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R01AI111205-10; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-19; FY total cost (award amount): 697200; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals